Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Virology,
Год журнала:
2025,
Номер
604, С. 110394 - 110394
Опубликована: Янв. 11, 2025
Язык: Английский
Reduced SARS-CoV-2 Infection Rates in Lab Workers Conducting Nucleic Acid Testing: Controlling for the Healthy Worker Effect
Journal of Epidemiology and Global Health,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 29, 2025
Язык: Английский
Next-Generation Coronavirus Disease 2019 Vaccines
Infectious Disease Clinics of North America,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years
npj Vaccines,
Год журнала:
2025,
Номер
10(1)
Опубликована: Март 17, 2025
The
intranasal
SARS-CoV-2
vaccine
dNS1-RBD
(Pneucolin®),
based
on
a
live-attenuated
influenza
virus
vector,
has
obtained
Emergency
Use
Authorization
in
China
for
individuals
aged
18
years
and
older.
Here,
we
conducted
single-center,
double-blind,
placebo-controlled,
age
de-escalation
phase
1
clinical
trial
to
evaluate
the
safety
of
children
3–17
(ChiCTR2300068044).
Sixty-three
participants
received
2
doses
or
placebo
at
days
0
14.
Safety
assessments
included
adverse
events/reactions
within
30
serious
events
(SAEs)
over
12
months.
Blood
nasal
secretion
samples
were
collected
further
monitor
blood
indices
viral
shedding.
group
showed
similar
reaction
rates
(39.0%
vs
36.4%),
with
no
SAEs
related
vaccination.
Data
suggested
that
is
well-tolerated
years,
warrants
studies
its
safety,
immunogenicity
efficacy
this
population.
Язык: Английский
Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters
PNAS Nexus,
Год журнала:
2024,
Номер
3(5)
Опубликована: Апрель 30, 2024
The
XBB.1.5
subvariant
has
garnered
significant
attention
due
to
its
exceptional
immune
evasion
and
transmissibility.
Significantly,
the
evolutionary
trajectory
of
SARS-CoV-2
shown
continual
progression,
with
a
recent
global
shift
observed
from
XBB
BA.2.86,
exemplified
by
emergence
predominant
JN.1
subvariant.
This
phenomenon
highlights
need
for
vaccines
that
can
provide
broad-spectrum
antigenic
coverage.
In
this
study,
we
utilized
NS1-deleted
(dNS1)
influenza
viral
vector
engineer
an
updated
live-attenuated
vectored
vaccine
called
dNS1-XBB-RBD.
encodes
receptor-binding
domain
(RBD)
protein
strain.
Our
findings
demonstrate
dNS1-XBB-RBD
elicits
similar
systemic
mucosal
response
compared
prototypic
form,
dNS1-RBD.
hamsters,
provided
robust
protection
against
immune-evasive
strains
XBB.1.9.2.1
Beta.
Remarkably,
nasal
vaccination
dNS1-RBD,
which
ancestor
RBD
gene,
also
effectively
protected
hamsters
both
Beta
strains.
These
results
valuable
insights
about
influenza-vectored
present
promising
strategy
development
COVID-19
in
future.
Язык: Английский
El enigma del coronavirus – Nuevos conocimientos sobre el COVID prolongado – Vacunas
Revista Peruana de Ginecología y Obstetricia,
Год журнала:
2024,
Номер
70(1)
Опубликована: Апрель 3, 2024
Al
finalizar
el
año
2023,
parecía
que
SARS-CoV-2
estaba
siendo
controlado,
aunquesu
variante
JN.1
infectaba
con
mayor
facilidad,
hospitalizaciones
de
adultosmayores
y
los
no
vacunados,
pero
pocas
muertes.
Ahora
van
apareciendo
algunasluces
sobre
COVID
prolongado,
cómo
las
secuelas
afectan
órganos
vitales
yporqué
persisten
en
un
importante
número
personas.
Desafortunadamente,
elcerebro
es
uno
más
afectados.
Por
ello,
la
necesidad
vacunas.Consideramos
presente
actualización
al
empezar
2024,
haciendoun
reconocimiento
a
labor
Eric
Topol
como
comunicador
científico
queproporciona
variada
información
lo
viene
ocurriendo
SARS-CoV-2y
COVID-19.
Sobre
aprendido,
aparte
prepararnos
para
futuras
pandemias,consideramos
evitar
soledad,
buscar
apoyo
emocional,
practicarla
virtualidad
telemedicina,
seamos
creativos,
lavémonos
manos,
usemosmascarilla
nos
protejan
agentes
patógenos
aéreos
apoyemos
vacunas.